Logo

MorphoSys Surpasses 2005 Revenue, Profit Guidance as Receipts Surge 52 Percent

Feb 03, 2006

NEW YORK, Feb. 3 (GenomeWeb News) - MorphoSys today said that revenue for 2005 increased 52 percent, causing total receipts and profit to surpass earlier projections, according to preliminary financial data.

 

Total receipts for the 12 months ended Dec. 31, 2005, increased to €33.5 million ($40.2 million) from €22 million year over year.

 

Net income surged to €4.7 million from €300,000 last year.

 

The company had recently forecast that net income would be €3.5 million on revenues of €31.5 million. But an earlier-than-planned succession of performance-based payments within existing collaborations made shortly before the end of the year helped the company surpass those projections.

 

MorphoSys said it will publish its audited financial statements on Feb. 24.

Breaking News
The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.